Skip to content
MedsAcross

Medicine

Dapagliflozin and Metformin 5 mg/1000 mg extended-release tablet

Available on requestPrescription onlyUS FDAGeneric name

Dapagliflozin and Metformin 5 mg/1000 mg extended-release tablet is a generic prescription medicine for oral use, made by 8 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…

Key facts

Active ingredient (INN)
Dapagliflozin and Metformin
Brand
Sold under the generic name
Strength
5 mg/1000 mg
Dosage form
Extended-release tablet
Route
Oral
Packs
30 tablets, 60 tablets, 90 tablets and 19 more
Manufacturers
Macleods PharmaceuticalsIndiaAscend LaboratoriesIndiaAurobindo PharmaIndiaMicro LabsIndiaNovadoz PharmaceuticalsIndiaSun Pharmaceutical IndustriesIndiaLupinIndiaGolden State Medical Supply
Origin register
US FDA, United States
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
A10BD15 Dapagliflozin and Metformin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
16 March 2026
Identifiers
RxCUI 1593058, 1593068, 1593070 +1DailyMed set ID 4f890458-be94-4baf-b606-83a097e1e23e, 7d575ca8-9c1f-469d-a341-34daf2f036dd, 513bdf9f-774c-4f7f-935a-54d3885e80a4 +5NDC 72205-435, 33342-408, 59651-155 +5Application ANDA211479, ANDA211559, ANDA211489 +4

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
30 tablet, film coated, extended release in 1 bottle67877-620-30Ascend LaboratoriesIndia6 April 2026
60 tablet, film coated, extended release in 1 bottle67877-620-60Ascend LaboratoriesIndia6 April 2026
90 tablet, film coated, extended release in 1 bottle67877-620-90Ascend LaboratoriesIndia6 April 2026
400 tablet, film coated, extended release in 1 bottle59651-155-04Aurobindo PharmaIndia6 April 2026
30 tablet, film coated, extended release in 1 bottle59651-155-30Aurobindo PharmaIndia6 April 2026
60 tablet, film coated, extended release in 1 bottle59651-155-60Aurobindo PharmaIndia6 April 2026
60 tablet, extended release in 1 bottle70748-102-07LupinIndia17 April 2026
3 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack33342-408-06Macleods PharmaceuticalsIndia6 April 2026
30 tablet, extended release in 1 bottle33342-408-07Macleods PharmaceuticalsIndia6 April 2026
60 tablet, extended release in 1 bottle33342-408-09Macleods PharmaceuticalsIndia6 April 2026
90 tablet, extended release in 1 bottle33342-408-10Macleods PharmaceuticalsIndia6 April 2026
500 tablet, extended release in 1 bottle33342-408-15Macleods PharmaceuticalsIndia6 April 2026
30 tablet, film coated, extended release in 1 bottle42571-322-30Micro LabsIndia1 October 2026
60 tablet, film coated, extended release in 1 bottle42571-322-60Micro LabsIndia1 October 2026
90 tablet, film coated, extended release in 1 bottle42571-322-90Micro LabsIndia1 October 2026
30 tablet, film coated, extended release in 1 bottle72205-435-01Novadoz PharmaceuticalsIndia9 April 2026
400 tablet, film coated, extended release in 1 bottle72205-435-02Novadoz PharmaceuticalsIndia9 April 2026
60 tablet, film coated, extended release in 1 bottle72205-435-03Novadoz PharmaceuticalsIndia9 April 2026
30 tablet, film coated, extended release in 1 bottle63304-026-30Sun Pharmaceutical IndustriesIndia6 April 2026
400 tablet, film coated, extended release in 1 bottle63304-026-54Sun Pharmaceutical IndustriesIndia6 April 2026
60 tablet, film coated, extended release in 1 bottle63304-026-62Sun Pharmaceutical IndustriesIndia6 April 2026
60 tablet, film coated, extended release in 1 bottle84677-020-60Golden State Medical Supply16 March 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 29 October 2014Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Dapagliflozin and Metformin

Clinical summary

Dapagliflozin and Metformin is a fixed-dose combination of a biguanide and a sodium-glucose cotransporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. MedsAcross supplies Dapagliflozin and Metformin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Dapagliflozin and Metformin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Dapagliflozin and Metformin 5 mg/1000 mg extended-release tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.